FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1400-1402 May 2, 2002 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gifford, A. L. PubMed Citation

The rational use of a new drug or treatment should be based on the results of controlled clinical trials that are well designed, avoid bias, and include subjects representing the full range of patients who are likely to receive the treatment once it is marketed. In addition to age, sex, diet, underlying disease, and the concomitant use of other medications, race and genetic factors may play pivotal parts in the variability of subjects' responses to a medication.¹ Regrettably, minority groups are underrepresented in most clinical trials. Often, there are insufficient data to assess the effectiveness or safety of new drugs . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Mosenifar, Z. (2007). Population Issues in Clinical Trials. Proc Am Thorac Soc 4: 185-188 [Abstract] [Full Text]  
• Koehn, P. H. (2006). Transnational Migration, State Policy and Local Clinician Treatment of Asylum Seekers and Resettled Migrants: Comparative Perspectives on Reception Center and Community Health Care Practice in Finland. Global Social Policy 6: 21-56 [Abstract]  
• Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M., Taylor, A. L., Wright, J. T. Jr, Cooper, R. S., Psaty, B. M. (2005). Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 112: 3654-3666 [Full Text]  
• Embi, P. J., Jain, A., Clark, J., Bizjack, S., Hornung, R., Harris, C. M. (2005). Effect of a Clinical Trial Alert System on Physician Participation in Trial Recruitment. Arch Intern Med 165: 2272-2277 [Abstract] [Full Text]  
• Hussain-Gambles, M. (2004). South Asian patients' views and experiences of clinical trial participation. Fam Pract 21: 636-642 [Abstract] [Full Text]  
• Moreno-John, G., Gachie, A., Fleming, C. M., NApoles-Springer, A., Mutran, E., Manson, S. M., PErez-Stable, E. J. (2004). Ethnic Minority Older Adults Participating in Clinical Research: Developing Trust. J Aging Health 16: 93S-123S [Abstract]  
• Burchard, E. G., Avila, P. C., Nazario, S., Casal, J., Torres, A., Rodriguez-Santana, J. R., Toscano, M., Sylvia, J. S., Alioto, M., Salazar, M., Gomez, I., Fagan, J. K., Salas, J., Lilly, C., Matallana, H., Ziv, E., Castro, R., Selman, M., Chapela, R., Sheppard, D., Weiss, S. T., Ford, J. G., Boushey, H. A., Rodriguez-Cintron, W., Drazen, J. M., Silverman, E. K. (2004). Lower Bronchodilator Responsiveness in Puerto Rican than in Mexican Subjects with Asthma. Am. J. Respir. Crit. Care Med. 169: 386-392 [Abstract] [Full Text]  
• Helliwell, P. S., Ibrahim, G. (2003). Ethnic differences in responses to disease modifying drugs. Rheumatology (Oxford) 42: 1197-1201 [Abstract] [Full Text]  
• Drukker, A., Feinstein, S., Rinat, C., Rotem-Braun, A., Frishberg, Y. (2003). Cadaver-Donor Renal Transplantation of Children in Israel (1990-2001): Racial Disparities in Health Care Delivery?. Pediatrics 112: 341-344 [Abstract] [Full Text]  
• Chesney, R. W., Wyatt, R. J. (2003). Racial Disparities in Renal Transplantation in Children. Pediatrics 112: 409-411 [Full Text]  
• Okada, A. A. (2003). International Guidelines: All for One and One for All?. Arch Ophthalmol 121: 1043-1044 [Full Text]  
• Benowitz, N. L. (2002). Smoking Cessation Trials Targeted to Racial and Economic Minority Groups. JAMA 288: 497-499 [Full Text]